EsoBiotec
Turnover is estimated at about €46.0m, probably between €31.0m and €76.0m.
Balance sheet
balance sheet total €16.5m on 31-12-2025in €m
in €m
Position in the sector
75.3%
Higher than 73% of the 346 companies filing abbreviated accounts in research and development (NACE 72) in 2025.
4.07
Higher than 70% of the 327 companies filing abbreviated accounts in research and development (NACE 72) in 2025.
46.9%
Higher than 95% of the 339 companies filing abbreviated accounts in research and development (NACE 72) in 2025.
Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter · Staff: middle half
Staff
€278,692
Staff costs divided by the average number of full-time equivalents.
-12 employees
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202114 months |
|---|---|---|---|---|---|---|
| 18.0m | -1.8m | -976,230 | 1.5m | -180,495 | ||
| 14.7m | -1.5m | -913,844 | 1.5m | -182,518 | ||
| 6.8m | 5.3m | 1.5m | 4.0m | 509,183 | ||
| -1.2m | -95,822 | -2.7m | 964,648 | - | ||
| 12.4m | 1.4m | 4.8m | 4.8m | 3.8m | ||
| 75.3% | 35.0% | 36.5% | 69.3% | 48.6% | ||
| 4.07 | 1.76 | 8.38 | 10.00 | 9.26 | ||
| 0.33 | 1.86 | 1.74 | 0.44 | 1.06 | ||
| 62.3% | -457.4% | -112.4% | -19.9% | -8.6% | ||
| 46.9% | -160.0% | -41.1% | -13.8% | -4.2% | ||
| 50.29 | -57.04 | -25.84 | 65.18 | -88.28 |
EBIT margin not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202114 months |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
16.5m | 4.3m | 6.5m | 7.3m | 4.7m | |
21/28 |
501 | 980,799 | 1.1m | 1.9m | 481,483 | |
21 |
- | - | - | 682,638 | 449,509 | |
22/27 |
- | 979,735 | 1.1m | 1.2m | 31,116 | |
23 |
- | 209,454 | 219,285 | 240,779 | - | |
24 |
- | 319,205 | 369,468 | 993,247 | 31,116 | |
25 |
- | 451,076 | 508,579 | - | - | |
28 |
501 | 1,064 | 1,064 | 1,284 | 858 | |
29/58 |
16.5m | 3.3m | 5.4m | 5.4m | 4.3m | |
40/41 |
16.4m | 547,837 | 1.5m | 1.2m | 1.1m | |
40 |
- | 32,010 | 21,791 | 10,070 | 12,921 | |
41 |
16.4m | 515,827 | 1.4m | 1.2m | 1.1m | |
50/53 |
- | 1.4m | 2.5m | - | - | |
54/58 |
113,183 | 1.3m | 1.4m | 4.1m | 3.2m | |
490/1 |
- | 51,383 | 45,914 | 5,123 | 3,156 | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
16.5m | 4.3m | 6.5m | 7.3m | 4.7m | |
10/15 |
12.4m | 1.5m | 2.4m | 5.1m | 2.3m | |
10/11 |
15.4m | 12.3m | 6.3m | 6.3m | 2.5m | |
10 |
15.4m | 12.3m | 6.3m | 6.3m | 2.5m | |
100 |
15.4m | 12.3m | 6.3m | 6.3m | 2.5m | |
14 |
-3.0m | -10.7m | -3.9m | -1.2m | -198,317 | |
17/49 |
4.1m | 2.8m | 4.1m | 2.2m | 2.4m | |
17 |
- | 905,201 | 2.5m | 615,686 | - | |
170/4 |
- | 905,201 | 2.5m | 615,686 | - | |
42/48 |
4.0m | 1.9m | 645,837 | 536,801 | 459,553 | |
42 |
- | 231,943 | 220,770 | 176,435 | - | |
44 |
398,138 | 1.1m | 358,116 | 305,305 | 459,458 | |
440/4 |
398,138 | 1.1m | 358,116 | 305,305 | 459,458 | |
45 |
3.7m | 192,392 | 66,856 | 54,751 | - | |
450/3 |
3.6m | 42,532 | - | 62 | - | |
454/9 |
1,189 | 149,860 | 66,856 | 54,689 | - | |
47/48 |
- | 377,911 | 95 | 310 | 95 | |
492/3 |
18,220 | - | 997,809 | 1.1m | 2.0m | |
| Income statement | ||||||
76A |
42.6m | - | - | - | - | |
9900 |
26.8m | -761,751 | 483,654 | 2.2m | 82,332 | |
62 |
2.6m | 1.0m | 892,857 | 697,557 | 262,827 | |
630 |
6.9m | 5.4m | 1.8m | 2.5m | 15,800 | |
640/8 |
104,100 | - | - | - | - | |
66A |
6.0m | - | 567,027 | - | - | |
9901 |
11.1m | -7.2m | -2.7m | -1.1m | -196,295 | |
75/76B |
1.1m | 54,116 | 27,873 | 3 | 22 | |
75 |
1.1m | 54,116 | 27,873 | 3 | 22 | |
65/66B |
358,254 | 31,202 | 37,780 | 22,687 | 2,045 | |
65 |
358,254 | 31,202 | 37,780 | 22,687 | 2,045 | |
9903 |
11.8m | -7.1m | -2.7m | -1.1m | -198,317 | |
67/77 |
4.1m | -268,289 | -72,294 | -80,792 | - | |
9904 |
7.7m | -6.9m | -2.7m | -1.0m | -198,317 | |
9905 |
7.7m | -6.9m | -2.7m | -1.0m | -198,317 | |
| Appropriation of the result | ||||||
9906 |
-3.0m | -10.7m | -3.9m | -1.2m | -198,317 | |
14P |
-10.7m | -3.9m | -1.2m | -198,317 | - | |
| Social balance sheet | ||||||
9087 |
9.4 | 10.6 | 9.6 | 7 | 3.2 | |
Hours worked1013 |
14,794 | 17,681 | 16,604 | 12,340 | 5,904 | |
| Document | ||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 07-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 07-07-2026 | 2026-00275331 | |
| 31-12-2024 | full format | 08-07-2025 | 2025-00241917 | |
| 31-12-2023 | micro format | 27-06-2024 | 2024-00168882 | |
| 31-12-2022 | micro format | 29-06-2023 | 2023-00173621 | |
| 31-12-2021 | micro format | 05-07-2022 | 2022-20151103 |
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | - | 12 | 10 | 9 | 5 |
| full-time | - | 11 | 9 | 9 | 5 |
| part-time | - | 1 | 1 | 0 | - |
| in full-time equivalents | - | 11.8 | 9.6 | 9 | 5 |
| 9.4 | 10.6 | 9.6 | 7 | 3.2 | |
| On a permanent contract | - | 11 | 9 | 9 | 5 |
| Joined | 1 | 4 | 5 | 8 | 6 |
| Left | 13 | 2 | 4 | 4 | 1 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | €27,022 | €7,549 | €1.3m | €32,341 |
| Intangible fixed assets | €6.8m | €5.2m | €1.5m | €2.7m | €475,984 |
| Financial fixed assets | - | - | €125 | €606 | €858 |
| €6.9m | €5.4m | €1.8m | €2.5m | €15,800 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on EsoBiotec
The operating result for 2025 is a profit of €11.1m, after a loss of €7.2m in 2024. It is the highest result since 2022.
Debt's share of the balance-sheet total falls from 65.0% to 24.7%. Equity and debt are higher.
- 2024 Compared with 2023, the net result fell by 157%. The accounts now follow the full format, last year the micro format.
- 2022 Compared with 2021, the net result fell by 406%. The previous financial year ran 14 months, this one 12.
- 2022 Compared with 2021, equity rose by 119% and the balance sheet total by 54%. Capital increase of €3.8m (Official Gazette 16-06-2022).